Cardiorenal syndrome
- PMID: 37669785
- PMCID: PMC10479996
- DOI: 10.1503/cmaj.230226
Cardiorenal syndrome
Conflict of interest statement
Competing interests: Bourne Auguste has received speaking honoraria from Amgen and Baxter Healthcare. No other competing interests were declared.
References
-
- Rangaswami J, Bhalla V, Blair JEA, et al. . Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 2019;139:e840–78. - PubMed
-
- Smith GL, Lichtman JH, Bracken MB, et al. . Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006;47:1987–96. - PubMed
-
- Bhandari S, Mehta S, Khwaja A, et al. STOP ACEi Trial Investigators. Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med 2022;387:2021–32. - PubMed
-
- Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 2022;400:1788–801. - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources